Figure 6.

Targeting HSP90‐HDAC6 is effective in ESCC cells. A, In KYSE140 and KYSE180, combination of Tubastatin A and PU‐H71 significantly reduced cell viability in comparation with treatment of either inhibitor alone. B, Tubastatin A and PU‐H71Tubastatin A evoked a sharp decrease of cell migration. C, Cells treated with Tubastatin A and PU‐H71 exhibited lowest protein level of EGFR, phospho‐AKT and phospho‐ERK in comparation with Tubastatin A or PU‐H71 treatment alone. (*P < 0.05 vs the control group, ^# P < 0.05 vs the drug treatment group)